HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation

Transfusion

Volumn 43, Issue 10, 2003, Pages 1428-1432

  Laperche, Syria ^b   Morel, Pascal ^b   Deschaseaux, Marie ^b   Bouchardeau, Françoise ^b   Alimardani, Gulie ^b   Guillaume, Nicolas ^b   Rouger, Philippe ^b   Lefrère, Jean Jacques ^a  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RNA;

ADULT; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; BLOOD COMPONENT THERAPY; BLOOD DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; NUCLEIC ACID AMPLIFICATION; SCREENING TEST; SEROLOGY; VALIDATION PROCESS; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS TRANSMISSION; BLOOD; SAFETY; VIREMIA;

ADULT; BLOOD DONORS; HIV ANTIBODIES; HUMANS; SAFETY; VIREMIA;

EID: 0142040264     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00541.x     Document Type: Article

References (23)

1. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiol Donor Study. N Engl J Med 1996;334:1685-90.
2. Pillonel J, Laperche S, Saura C, et al. Trends in risk of transfusion-transmitted viral infections in France, 1992 to 2000. Transfusion 2002;42:980-8.
3. Degre M. International forum: 15. Vox Sang 2002;83:87-111.
4. Busch MP, Kleinman SH, Jackson B, et al. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000;40:143-59.
5. Roth WK, Weber M, Buhr S, et al. Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002;42:862-8.
6. Glynn SA, Kleinman SH, Wright DJ, Busch MP. International application of the incidence rate/window period model. Transfusion 2002;42:966-72.
7. Alvarez M, Oyonarte S, Rodriguez PM, Hernandez JM. Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion 2002;42:994-8.
8. Velati C, Romano L, Baruffi L, et al. Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion 2002;42:989-93.
9. Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-9.
10. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000;181:872-80.
11. Ling AE, Robbins KE, Brown TM, et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000;284:210-4.
12. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rer 1992;41:1-19.
13. Lefrere JJ, Morand-Joubert L, Mariotti M, et al. Even individuals considered as long-term nonprogressors show biological signs of progression after 10 years of human immunodeficiency virus infection. Blood 1997;90:1133-40.
14. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-8.
15. Mulder J, Resnick R, Saget B, et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997;35:1278-80.
16. Barin F, Lahbabi Y, Buzelay L, et al. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res Hum Retroviruses 1996;12:1279-89.
17. Stramer SL. NAT update: where are we today? Dev Biol (Basel) 2002;108:41-56.
18. Linnen JM, Gilker JM, Menez A, et al. Sensitive detection of genetic variants of HIV-1 and HCV with an HIV-1/HCV assay based on transcription-mediated amplification. J Virol Methods 2002;102:139-55.
19. Lelie PN, van Drimmelen HA, Cuypers HT, et al. Sensitivity of HCV RNA and HIV RNA blood screening assays. Transfusion 2002;42:527-36.
20. Vargo J, Smith K, Knott C, et al. Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. Transfusion 2002;42:876-85.
21. AuBuchon JP, Pickard CA, Herschel LH, et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion 2002;42:146-52.
22. Van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
23. Corash L. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives. Transfus Med Rev 1999;13:18-30.